glp 1 gip glucagon triple agonist retatrutide mechanism glp-1 GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation Calling retatrutide a “GLP-3” is
Description
A recent AMA/CDC report covered the challenges with long term adherence and the introduction of new indications will drive the need for ongoing research incorporating richer data sources beyond claims
Glucagon-Like peptide-1 receptor agonists
Novo Nordisk filed its New Drug Application with the FDA on 18 December 2025, based on data from the REDEFINE 1 trial
doi: 10.1016/j.numecd.2021.08.049, 34
T., Kaufman, K
A total of 63.2% of the patients in the liraglutide arm lost at least 5% of their body weight compared with 27.1% in the placebo arm ( P 30% (79)
